Telix Pharmaceuticals gets FDA fast track for BiPASS pre-biopsy prostate imaging
Telix said the FDA granted Fast Track status for its BiPASS pre-biopsy prostate imaging program, with Illuccix and Gozellix approved for PET imaging of PSMA-positive prostate cancer lesions.
Sept. 30 (Reuters) — Telix Pharmaceuticals Limited said the U.S. Food and Drug Administration has granted fast track designation for BiPASS pre-biopsy prostate imaging. The company said Illuccix and Gozellix are approved for PET imaging of PSMA-positive prostate cancer lesions.
Further company coverage: TLX.AX (Reuters.Briefs@thomsonreuters.com;)